{
  "docId": "019de071-b48b-74ad-8fcb-69ba4c0494fb",
  "docSlug": "4047dd7a7e0f28ca31128b58ef648c55",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 39,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide contrasts financial performance (bar chart) with clinical development milestones (bulleted list).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b48b-74ad-8fcb-69ba4c0494fb/31",
  "deckHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb",
  "deckJsonHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb.json",
  "deckAnchorHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.04,
        "y": 0.27
      },
      "kind": "chart",
      "text": "Pro-forma global growth, Q3 2021",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f422a37-5ed9-4965-a8c7-52442176fc26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.53,
        "y": 0.43
      },
      "kind": "list",
      "text": "Positive Phase III results for Ultomiris in generalised myasthenia gravis; Phase III trial for Ultomiris in amyotrophic lateral sclerosis stopped for futility on IDMC recommendation; Positive Phase III results for ALXN1840 in Wilson disease; Acquired Caelum Biosciences: CAEL-101 Phase III development in AL amyloidosis to be accelerated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59d52020-43ec-4061-ae42-6a8d9e82745c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.03,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "IMDC = Independent Data Monitoring Committee; AL = amyloid light-chain. 1. geographic splits restated.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f59eb953-50e0-48c0-889b-0ee23b0cfc4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.36,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Rare Disease Q3 2021 Total Revenue $1.3bn",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "167a5569-7182-4c9a-9979-2e029b848ea7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.42,
        "x": 0.53,
        "y": 0.27
      },
      "kind": "title",
      "text": "Multiple Phase III results across both LCM and NMEs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "984f7ea9-a10b-4a9d-8383-d27915eaf260",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}